U.S. Markets closed

Constellation Pharmaceuticals, Inc. (CNST)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
25.79+0.34 (+1.34%)
At close: 1:00PM EST
Sign in to post a message.
  • Y
    Yahoo Finance Insights
    Constellation is up 9.23% to 22.96
  • H
    Hugh
    why would anybody buy now? There's no news for years. Why even own it now? They can't accelerate with more cash.
  • H
    Hugh
    Genotoxciity??? for a treatment that desperately needs to avoid turning into leukemia?
    Bearish
  • Y
    Yahoo Finance Insights
    Constellation is up 9.21% to 23.47
  • K
    Kimleng
    the company has 523 millions in cash. and the company value is 820 millions.
  • C
    Chris
    After today's news Oppenheimer raised their target price on CNST to $40 from $18 - maintaining an outperform rating
  • d
    dave
    $21 Price Target by Oppenheimer. Today $8.75 REBOUND? Oppenheimer Thinks Constellation Pharmaceuticals Inc’s Stock is Going to Recover
    In a report released Dec 11, 2018, Leah R. Cann from Oppenheimer initiated coverage with a Buy rating on Constellation Pharmaceuticals Inc (CNST) and a price target of $21.
  • s
    stiglg6
    I think the disease modifying activity indicated by the manifest trial hints that a combination therapy with imetelstat would be beneficial.
  • Y
    Yahoo Finance Insights
    Constellation is up 9.34% to 22.36
  • s
    stiglg6
    . CNSTs BET inhibitor, slows down growth, and somehow activates caspases downstream to kill the cell. this is the same thing that geron's imetelstat does. onyl difference being that telomerase is upregulated in 90% of all cancer cell lines while BET is only upregulated in some.

    only the preliminary results have been reported by CNST
    the BETi only works in some cancer cell lines so they decided not to risk it and go straight to combos.
    on the other hand, imetelstat, capable of working on 90% of cancer cell lines as usually lended to single agent trials to demonstrate baseline efficacy and safety.
    we have good reason to believe imetelstat would work in combo with jakafi and CNST's BETi.

    Right now imetelstat has demonstrated a 21 month surivival advantage in the r/r MF cohort that was expected to live 12 months.

    the frontline treatment (jakafi) only yielded an 18 month survival advantage of patients that were expected to live 3.6 years.

    imetelstat is 3 times better than the frontline and there is a preclinical showing it would work well in combo with the frontline. all this hype over CNST's preliminary data is undeserved.
  • s
    s p
    got a few shares not going in too deep right off the bat. Most of these newly listed drop like a rock.
  • R
    Richard
    love to know offering price
  • B
    Ballsio
    this is funny, investors taken to the wood shed as it was $20 dollars higher this morning. selling the profits for year end tax management maybe? Bring those profits over to GERN gullable ones.
  • Y
    Yahoo Finance Insights
    Constellation is down 8.86% to 21.30
  • b
    biotexx
    $GERN conversation
    @noBALLSio $CNST the plunge seemed to be a short term buying opportunity. Climbed back up to $40. Just 3 months ago we were around $6... but yes...it feels like high risk this could be imploding any time. Just like here at $GERN... 😂😂😂
  • J
    Joseph
    looks like funds who bought at $35 are waking up and buying at $20-22
  • B
    Ballsio
    man, that is like $650M market cap. lost in 5 hours. Ouchey.
  • L
    Lorax
    missed the boat on this one... congrats to all longs!
  • J
    Joseph
    Oppenheimer investor conference today.anyone listen ?
  • F
    F0RD1
    Would anyone on this board know the history/timeline on CPI-1205? My father in law just went on it last week to help battle his prostate cancer. It sounds like he is one of a few in the trials for prostate and I'm trying to find more information. He has a checkup on Monday so hopefully the initial news is good. Thank you for any feedback.